Poor AZ. Developing the stroke treatment Cerovive must be no fun at all. The pressure must be intense, given that it's half of all their Phase 3 development options (the other being the PPAR agonist Galida!!).
So when Tomas Odergren, who heads the development programme for the drug at AstraZeneca, said the news that the SAINT studys' independent safety board has OK'd the trial to continue he was inferring that this was another encouraging sign that Cerovive is well tolerated in acute ischemic stroke patients, who have tended to be highly vulnerable to adverse effects of many other drug candidates tested to date.
A case of no bad news being good news? Maybe?
No comments:
Post a Comment